NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • March 20th, 2014 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
AGREEMENT made as of the [_____________], 20[__], between Interleukin Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business at 135 Beaver Street, Waltham, Massachusetts 02452, and, a [director/consultant/employee] of the Company (the “Participant”).
INCENTIVE STOCK OPTION AGREEMENT INTERLEUKIN GENETICS, INC.Incentive Stock Option Agreement • March 20th, 2014 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
AGREEMENT made as of the [_____] day of [_______] 20[___], between Interleukin Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Waltham, Massachusetts, and [_________________], an employee of the Company (the “Employee”).
FIRST AMENDED PREFERRED PARTICIPATION AGREEMENTParticipation Agreement • March 20th, 2014 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Massachusetts
This FIRST AMENDED PREFERRED PARTICIPATION AGREEMENT (this “First Amended Agreement”) is entered into as of November 1, 2013 (“Effective Date”), by and between Interleukin Genetics, Inc., a Delaware corporation with an address of 135 Beaver Street, Waltham, MA 02452, (“Interleukin”), and Renaissance Health Service Corporation, and on behalf of its affiliates, with its principal place of business at 4100 Okemos Road, Okemos, Michigan 48864, (collectively, “RHSC”). Interleukin and RHSC may be referred to herein individually as a “Party” and collectively as the “Parties.”
